Metabolic & Incretin Research Guide

SLU-PP-332: Mechanism, Handling & Research Guide

Also known as: SLU PP 332, SLU-PP-332, pan-ERR agonist, ERR agonist, exercise mimetic, ERRalpha agonist

Key Facts

SLU-PP-332 is a metabolic & incretin research peptide. Synthetic research peptide for neuromodulatory and metabolic studies. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification	Synthetic small-molecule pan-agonist of estrogen-related receptors (ERR alpha/beta/gamma); investigational exercise-mimetic research tool (note: small molecule, not a peptide)
Research Half-Life	Not well characterized; described in preclinical reports as having relatively short systemic exposure, but no validated human pharmacokinetic half-life is established (preclinical compound).
Form	Lyophilized powder
Research Category	Metabolic & Incretin

What is SLU-PP-332?

SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors (ERRs), specifically ERR-alpha, ERR-beta, and ERR-gamma. These orphan nuclear receptors regulate the transcription of genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism. Research from the Bhatt laboratory at Saint Louis University (published in ACS Chemical Biology, 2023) demonstrated that SLU-PP-332 use in mouse models increased exercise endurance and fatigue resistance without physical training, earning it attention as a potential exercise mimetic compound. The mechanism involves upregulating PGC-1alpha-dependent gene networks that modulate mitochondrial density and oxidative capacity in skeletal muscle. In ischemic stroke models, ERR activation by SLU-PP-332 has shown neuroprotective effects by preserving mitochondrial membrane integrity and reducing reactive oxygen species production (Willy et al., published in Cell Chemical Biology). Compared to other exercise mimetics such as AICAR (AMPK activator) or GW501516 (PPAR-delta agonist), SLU-PP-332 targets a distinct upstream transcriptional pathway that coordinately activates multiple metabolic gene programs rather than a single signaling cascade. Research also suggests potential applications in chronic fatigue and neurodegenerative conditions where mitochondrial dysfunction is implicated. Store lyophilized powder at -20C in a desiccated environment; reconstitute in DMSO or appropriate vehicle per study specifications. SLU-PP-332 is investigated by exercise physiology researchers, neuroscience departments studying metabolic neuroprotection, and pharmacology labs exploring nuclear receptor biology.

SLU-PP-332 Research Applications

In published and preclinical research, SLU-PP-332 has been studied across the following areas:

Neuroprotection and ischemic stroke models
Cognition and BDNF-pathway research
Mitochondrial and chronic fatigue therapies
Incretin and metabolic pathways

SLU-PP-332 in Research: Study Context

Published preclinical literature characterizes SLU-PP-332 as a synthetic pan-ERR agonist (highest potency at ERR alpha) that activates ERR-dependent transcriptional programs governing mitochondrial biogenesis, oxidative phosphorylation, and fatty-acid oxidation. In sedentary mice, Billon et al. (ACS Chemical Biology 2023) reported that it induced an ERR alpha-dependent acute aerobic-exercise gene program in skeletal muscle and increased treadmill running time/distance, and a companion study (Billon et al., JPET 2024) reported improvements in energy expenditure, fat mass, and insulin sensitivity in obesity/metabolic-syndrome models. This compound is for laboratory research use only and is NOT FDA-approved; the evidence is preclinical (rodent/in vitro) with no established human. SLU-PP-332 is a small molecule typically dissolved in DMSO/vehicle per study; where a peptide-style aqueous prep is used in a lab, the powder is reconstituted to a defined concentration (e.g., 5 mg in 1 mL = 5 mg/mL) - investigators should follow solubility guidance, reference the primary literature, and document the lot-specific COA.

How SLU-PP-332 Compares

Researchers frequently evaluate SLU-PP-332 alongside related compounds:

SLU-PP-332 vs 5-Amino-1MQ — Both are studied as small-molecule metabolic research tools, but via different mechanisms: SLU-PP-332 is an ERR agonist driving mitochondrial/oxidative gene programs, whereas 5-Amino-1MQ is investigated as an NNMT inhibitor affecting NAD+/methylation-linked adipocyte metabolism.
SLU-PP-332 vs MOTS-c — Both appear in metabolic/exercise-physiology research, but MOTS-c is a mitochondrial-derived peptide studied around AMPK signaling and insulin sensitivity, while SLU-PP-332 is a synthetic ERR-agonist small molecule acting at the nuclear-receptor/transcriptional level.

SLU-PP-332 — Frequently Asked Questions

What does SLU-PP-332 target at the molecular level?

It is a synthetic agonist of the estrogen-related receptors ERR alpha, ERR beta, and ERR gamma (with greatest potency at ERR alpha). These orphan nuclear receptors sit upstream of PGC-1 alpha-coordinated gene networks controlling mitochondrial biogenesis and oxidative metabolism, which is why published rodent studies describe an exercise-like transcriptional signature in skeletal muscle. This is a research mechanism, not an approved indication.

Why is it called an exercise mimetic in the literature?

Because in mouse studies (Billon et al., ACS Chem Biol 2023) it activated an ERR alpha-dependent acute aerobic-exercise gene program and increased running endurance in untrained animals without physical training. The term describes a preclinical pharmacological observation; it does not imply equivalence to exercise or any validated benefit in humans.

Is SLU-PP-332 a peptide, and what is the state of evidence?

No - it is a synthetic small molecule (an ERR ligand), not a peptide. The evidence is preclinical, drawn from cell assays and rodent metabolic/endurance models; there are no controlled human data, it is not FDA-approved, and no human concentration is established. It is intended strictly for laboratory research.

How is SLU-PP-332 handled in the laboratory?

As a small molecule it is commonly prepared in DMSO or another study-appropriate vehicle per solubility guidance; some labs prepare an aqueous working stock by reconstituting the powder with bacteriostatic water to a defined concentration (for a 5 mg vial, 1 mL yields 5 mg/mL). Store as directed, avoid repeated freeze-thaw, and verify identity/purity against the lot-specific COA. No human concentration is defined.

Is SLU-PP-332 legal to buy for research?

SLU-PP-332 is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.

Does SLU-PP-332 come with a Certificate of Analysis?

Yes. Every batch of SLU-PP-332 from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.

What is SLU-PP-332 and how does it work?

SLU-PP-332 is a synthetic compound that functions as an agonist of estrogen-related receptors (ERRs), particularly ERR-alpha, ERR-beta, and ERR-gamma. These nuclear receptors regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism. In preclinical studies, SLU-PP-332 has been observed to modulate exercise-related gene expression in skeletal muscle without actual physical activity.

What research has been done on SLU-PP-332?

Research from the Bhatt Lab at Saint Louis University (published in Journal of Pharmacology and Experimental Therapeutics) demonstrated that SLU-PP-332 activated ERR-dependent transcriptional programs in muscle tissue. Mouse studies showed increased running endurance and improved resistance to diet-induced obesity. Additional research has explored its neuroprotective potential in ischemic stroke models and chronic fatigue conditions.

How does SLU-PP-332 compare to GW501516 (Cardarine)?

While both compounds have been studied as exercise mimetics, they act through different nuclear receptor pathways. GW501516 targets PPAR-delta, whereas SLU-PP-332 activates ERR-alpha/beta/gamma receptors. ERRs sit upstream of many mitochondrial genes, giving SLU-PP-332 a broader metabolic profile in preclinical models. GW501516 has raised safety concerns in long-term rodent studies that have not been observed with SLU-PP-332.

Research References

All research guides